PF-06372865 + lorazepam

PF-06372865 + lorazepam is an experimental combination of two central nervous system agents: PF-06372865, a selective positive allosteric modulator (PAM) of the γ-aminobutyric acid type A (GABA-A) receptor targeting the α2/3/5 subunits, and lorazepam, a classical benzodiazepine acting as a non-selective positive allosteric modulator at GABA-A receptors. PF-06372865 is designed to enhance GABA signaling with reduced sedative and cognitive side effects by selectively sparing α1 subunit activity, while lorazepam provides broad anxiolytic, anticonvulsant, and sedative properties. The combination has been studied for the suppression of epileptic activity, especially in photoepilepsy models, and both agents independently showed significant decreases in epileptiform EEG activity compared to placebo, with tolerability established in short trial settings. PF-06372865 was developed by Pfizer, and lorazepam was originally developed by Wyeth.

Brand names

AtivanLoreev

Other names

lorazepamo-Chlorooxazepamo-Chloroxazepam